NASDAQ:ABVX ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis $10.35 +0.22 (+2.17%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About ABIVAX Société Anonyme Stock (NASDAQ:ABVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ABIVAX Société Anonyme alerts:Sign Up Key Stats Today's Range$9.86▼$10.5850-Day Range$8.97▼$12.7152-Week Range$7.99▼$17.02Volume94,465 shsAverage Volume90,840 shsMarket Capitalization$651.32 millionP/E RatioN/ADividend YieldN/APrice Target$36.50Consensus RatingModerate Buy Company OverviewABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Read More… Retire off just one stock ticker? (Ad)ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...Click here for the ticker >>> ABIVAX Société Anonyme Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreABVX MarketRank™: ABIVAX Société Anonyme scored higher than 52% of companies evaluated by MarketBeat, and ranked 613th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingABIVAX Société Anonyme has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageABIVAX Société Anonyme has only been the subject of 1 research reports in the past 90 days.Read more about ABIVAX Société Anonyme's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ABIVAX Société Anonyme are expected to grow in the coming year, from ($2.98) to ($2.86) per share.Price to Book Value per Share RatioABIVAX Société Anonyme has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.49% of the float of ABIVAX Société Anonyme has been sold short.Short Interest Ratio / Days to CoverABIVAX Société Anonyme has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABIVAX Société Anonyme has recently increased by 31.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldABIVAX Société Anonyme does not currently pay a dividend.Dividend GrowthABIVAX Société Anonyme does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.49% of the float of ABIVAX Société Anonyme has been sold short.Short Interest Ratio / Days to CoverABIVAX Société Anonyme has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABIVAX Société Anonyme has recently increased by 31.50%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment0.95 News SentimentABIVAX Société Anonyme has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ABIVAX Société Anonyme this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ABIVAX Société Anonyme insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of ABIVAX Société Anonyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ABIVAX Société Anonyme's insider trading history. Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABIVAX Société Anonyme and its competitors with MarketBeat's FREE daily newsletter. Email Address ABVX Stock News HeadlinesShort Interest in ABIVAX Société Anonyme (NASDAQ:ABVX) Increases By 31.5%October 14 at 4:20 AM | americanbankingnews.comABIVAX Société Anonyme (NASDAQ:ABVX) Shares Gap Up - Here's WhyOctober 13, 2024 | americanbankingnews.comHere’s how to start a “Weekend Side Hustle” from your sofaHere’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand. And that’s how you can kickstart your very own “Weekend Side Hustle!” Now that you know that…October 17, 2024 | DTI (Ad)Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene RegulationOctober 7, 2024 | globenewswire.comAbivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's DiseaseOctober 3, 2024 | globenewswire.comAbivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label MaintenanceOctober 3, 2024 | globenewswire.comAbivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024September 26, 2024 | globenewswire.comAbivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse ModelSeptember 25, 2024 | globenewswire.comSee More Headlines ABVX Stock Analysis - Frequently Asked Questions How have ABVX shares performed this year? ABIVAX Société Anonyme's stock was trading at $10.70 at the beginning of the year. Since then, ABVX shares have decreased by 3.3% and is now trading at $10.35. View the best growth stocks for 2024 here. When did ABIVAX Société Anonyme IPO? ABIVAX Société Anonyme (ABVX) raised $217 million in an initial public offering (IPO) on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60 per share. How do I buy shares of ABIVAX Société Anonyme? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ABIVAX Société Anonyme own? Based on aggregate information from My MarketBeat watchlists, some other companies that ABIVAX Société Anonyme investors own include Adverum Biotechnologies (ADVM), APi Group (APG), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Boot Barn (BOOT), G1 Therapeutics (GTHX) and Howard Hughes (HHH). Company Calendar Today10/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CUSIPN/A CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$36.50 High Stock Price Target$50.00 Low Stock Price Target$16.00 Potential Upside/Downside+252.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.48 Current Ratio3.04 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.37 per share Price / Book3.07Miscellaneous Outstanding Shares62,929,000Free FloatN/AMarket Cap$651.32 million OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:ABVX) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABIVAX Société Anonyme Please log in to your account or sign up in order to add this asset to your watchlist. Share ABIVAX Société Anonyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.